Hamdan Medical Journal (previously the Journal of Medical Sciences)

Table of Contents  

Management of Febrile Neutropenia

Michael Ellis
Published in : Journal of Medical Sciences ; Vol 1, No 2 (2008)
DOI : 10.2174/1996327000801020010


The significant successes in hematological cancer chemotherapy in the last 40 years have been tempered through the ‘innocent casualty’ phenomenon of creating a highly immunocompromised milieu fruitful for opportunistic infections, whose morbidity and mortality threaten outcome.


View article in  :   PDF    


Vento S, Cainelli F. Infections in patients with cancerundergoing chemotherapy: aetiology, prevention, and treatment. Lancet Oncol 2003; 4(10): 595-604.

Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966;64(2): 328-40.

Schimpff SC, Gaya H, Klastersky J, Tattersall MH,Zinner SH. Three antibiotic regimens in the treatment ofinfection in febrile granulocytopenic patients with cancer.The EORTC international antimicrobial therapy projectgroup. J Infect Dis 1978; 137(1): 14-29.

Viscoli C, Castagnola E. Factors predisposing cancer patients to infection. Cancer Treat Res 1995; 79:1-30.

Elting LS, Bodey GP, Keefe BH. Septicemia and shock syndrome due to viridans streptococci: a case-control study of predisposing factors. Clin Infect Dis 1992;14(6): 1201-7.

De Bock R, et al. Incidence of single agent Gramnegative bacteremias (SAGNB) in neutropenic cancer patients (NCP) in EORTC-IATG trial of empirical therapy for febrile neutropenia [abstract L-773]. In Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago).Washington, DC.: American Society for Microbiology 2001, 445.

Cappellano P, et al. Bloodstream infections (BSI) due to Enterococcus sp. In allogenic bone marrow transplantation (ALLOBMT) [abstract 11CD]. In:Scientific program and abstracts of the 6th International Symposium on Febrile Neutropenia (Brussels). Alpharetta, GA: Imedex, 2003.

Fridkin SK. The changing face of fungal infections in health care settings. Clin Infect Dis 2005; 41(10): 1455- 60.

Vahaboglu H, Coskunkan F, Tansel O, Ozturk R, Sahin N,Koksal I, et al. Clinical importance of extended-spectrum beta-lactamase (PER-1-type)-producing Acinetobacter spp. and Pseudomonas aeruginosa strains. J Med Microbiol 2001; 50(7): 642-5.

Marr KA, Seidel K, Slavin MA, Bowden RA, Schoch HG, Flowers ME, et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasisrelated death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood 2000; 96(6): 2055-61.

Vahaboglu H, Oztürk R, Aygün G, Coskunkan F, Yaman A, Kaygusuz A, et al. Widespread detection of PER-1-type extended-spectrum beta-lactamases among nosocomial Acinetobacter and Pseudomonas aeruginosa isolates in Turkey: a nationwide multicenter study. Antimicrob Agents Chemother 1997; 41(10): 2265-9.

Marr KA, Seidel K, White TC, Bowden RA. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis 2000; 181(1): 309-16.

Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34(7): 909-17.

Marr KA, Carter RA, Boeckh M, Martin P, Corey L.Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002; 100(13): 4358-66.

Pagano L, Girmenia C, Mele L, Ricci P, Tosti ME, Nosari A, et al. Infections caused by filamentous fungi in patients with hematologic malignancies. A report of 391 cases by GIMEMA Infection Program. Haematologica 2001; 86(8): 862-70.

Martino R, Subira M. Invasive fungal infections in hematology: new trends. Ann Hematol 2002; 81(5): 233-43.

Bodey G, Bueltmann B, Duguid W, Gibbs D, Hanak H, Hotchi M, et al. Fungal infections in cancer patients: an international autopsy survey. Eur J Clin Microbiol Infect Dis 1992; 11(2): 99-109.

Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001; 32(3): 358-66.

Richardson MD. Changing patterns and trends in systemic fungal infections. J Antimicrob Chemother 2005; 56 Suppl1: i5-i11.

Kontoyiannis DP, Lewis RE. Invasive zygomycosis: update on pathogenesis, clinical manifestations, and management. Infect Dis Clin North Am 2006; 20(3): 581-607, vi.

Steinbach WJ, Perfect JR, Schell WA, Walsh TJ, Benjamin DK Jr. In vitro analyses, animal models, and 60 clinical cases of invasive Aspergillus terreus infection. Antimicrob Agents Chemother 2004; 48(9): 3217-25.

Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34(6): 730-51.

Schimpff S, Satterlee W, Young VM, Serpick A. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. N Engl J Med 1971; 284(19):1061-5.

Sharma A, Lokeshwar N. Febrile neutropenia in haematological malignancies. J Postgrad Med 2005; 51 Suppl 1: S42-8.

Kern WV. Risk assessment and treatment of low-risk patients with febrile neutropenia. Clin Infect Dis 2006; 42(4): 533-40.

de Lalla F. Outpatient therapy for febrile neutropenia: clinical and economic implications. Pharmacoeconomics 2003; 21(6): 397-413.

Chisholm JC, Dommett R. The evolution towards ambulatory and day-case management of febrile neutropenia. Br J Haematol, 2006; 135(1): 3-16.

Talcott JA, Siegel RD, Finberg R, Goldman L. Risk assessment in cancer patients with fever and neropenia: a prospective, two-center validation of a prediction rule.J Clin Oncol 1992; 10(2): 316-22.

Klastersky J, Paesmans M, Rubenstein EB, Boyer M,Elting L, Feld R, et al. The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000; 18(16): 3038-51.

Persson L, Söderquist B, Engervall P, Vikerfors T, Hansson LO, Tidefelt U. Assessment of systemic inflammation markers to differentiate a stable from a deteriorating clinical course in patients with febrile neutropenia. Eur J Haematol 2005; 74(4): 297-303.

Persson L, Engervall P, Magnuson A, Vikerfors T,Söderquist B, Hansson LO, et al. Use of inflammatory markers for early detection of bacteraemia in patients with febrile neutropenia. Scand J Infect Dis 2004; 36(5):365-71.

Hodge G, Osborn M, Hodge S, Nairn J, Tapp H,Kirby M, et al. Rapid simultaneous measurement of multiple cytokines in childhood oncology patients with febrile neutropenia: increased interleukin (IL)-8 or IL-5 correlates with culture-positive infection. Br J Haematol 2006; 132(2): 247-8.

Gafter-Gvili A, Fraser A, Paul M, Leibovici L. Metaanalysis:antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 2005; 142(12 Pt1): 979-95.

Cullen M, Steven N, Billingham L, Gaunt C, Hastings M, Simmonds P, et al. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med 2005; 353(10): 988-98.

Bucaneve G, Micozzi A, Menichetti F, Martino P, Dionisi MS, Martinelli G, et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 2005; 353(10): 977-87.

Gafter-Gvili A, Paul M, Fraser A, Leibovici L. Effect of quinolone prophylaxis in afebrile neutropenic patients on microbial resistance: systematic review and metaanalysis.J Antimicrob Chemother 2007; 59(1): 5-22.

Leibovici L, Paul M, Cullen M, Bucaneve G, Gafter-Gvili A, Fraser A, et al. Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions. Cancer2006; 107(8): 1743-51.

Ellis M. Preventing microbial translocation in haematological malignancy. British Journal of Haematology 2004; 125: 282-293.

Ellis M, Zwaan F, Hedström U, Poynton C, Kristensen J, Jumaa P, et al. Recombinant human interleukin 11 and bacterial infection in patients with haematological malignant disease undergoing chemotherapy: a doubleblind placebo-controlled randomised trial. Lancet 2003;361(9354): 275-80.

van Saene HK, Petros AJ, Ramsay G, Baxby D. 2003. All great truths are iconoclastic: selective decontamination of the digestive tract moves from heresy to level 1 truth.Intensive Care Med 2003; 29(5): 677-90.

EORTC International Antimicrobial Therapy Cooperative Group Empiric antifungal therapy in febrile granulocytopenic patients. EORTC International Antimicrobial Therapy Cooperative Group. American Journal of Medicine 1989; 86: 668-672.

Ostrosky-Zeichner L, Marr KA, Rex JH, Cohen SH.Amphotericin B: time for a new “gold standard”. Clin Infect Dis 2003; 37(3): 415-25.

Anaissie E, Paetznick V, Proffitt R, Adler-Moore J, Bodey GP. Comparison of the in vitro antifungal activity of free and liposome-encapsulated amphotericin B. Eur J Clin Microbiol Infect Dis, 1991; 10(8): 665-8.

Garcia A, Adler-Moore JP, Proffitt RT. Single-dose AmBisome (Liposomal amphotericin B) as prophylaxis for murine systemic candidiasis and histoplasmosis.Antimicrob Agents Chemother 2000; 44(9): 2327-32.

Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999;340(10): 764-71.

Walsh TJ, Pappas P, Winston DJ, Lazarus HM, Petersen F,Raffalli J, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. Engl J Med 2002; 346(4): 225-34.

Walsh TJ, Teppler H, Donowitz GR, Maertens JA, Baden LR, Dmoszynska A, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004; 351(14): 1391-402.

Bowman JC, Hicks PS, Kurtz MB, Rosen H, Schmatz DM,Liberator PA, et al. 2002. The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro. Antimicrob Agents Chemother 2002;46(9): 3001-12.

Ellis M, Frampton C, Joseph J, Alizadeh H, Kristensen J,Hauggaard A, et al. An open study of the comparative efficacy and safety of caspofungin and liposomal amphotericin B in treating invasive fungal infections or febrile neutropenia in patients with haematological malignancy. J Med Microbiol 2006; 55(Pt 10): 1357-65.

Martino R, Viscoli C. Empirical antifungal therapy in patients with neutropenia and persistent or recurrent fever of unknown origin. Br J Haematol 2006; 132(2):138-54.

Hauggaard A, Ellis M, Ekelund L. Early chest radiography and CT in the diagnosis, management and outcome of invasive pulmonary aspergillosis. Acta Radiol 2002;43(3): 292-8.

Caillot D, Casasnovas O, Bernard A, Couaillier JF,Durand C, Cuisenier B, et al. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol 1997; 15(1):139-47.

Horger M, Einsele H, Schumacher U, Wehrmann M, Hebart H, Lengerke C, et al. Invasive pulmonary aspergillosis: frequency and meaning of the “hypodense sign” on unenhanced CT. Br J Radiol 2005; 78(932):697-703.

Greene RE, Schlamm HT, Oestmann JW, Stark P, Durand C, Lortholary O, et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis 2007; 44(3): 373-9.

Ostrosky-Zeichner L, Alexander BD, Kett DH, Vazquez J,Pappas PG, Saeki F, et al. Multicenter clinical evaluation of the (1-->3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 2005; 41(5): 654-9.

Odabasi Z, Mattiuzzi G, Estey E, Kantarjian H, Saeki F,Ridge RJ, et al. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development,and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 2004; 39(2): 199-205.

Maertens J, Verhaegen J, Demuynck H, Brock P,Verhoef G, Vandenberghe P, et al. Autopsy-controlled prospective evaluation of serial screening for circulatinggalactomannan by a sandwich enzyme-linked immunosorbent assay for hematological patients at risk for invasive Aspergillosis. J Clin Microbiol 1999; 37(10):3223-8.

Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a metaanalysis.Clin Infect Dis 2006; 42(10): 1417-727.

Marr KA, Balajee SA, McLaughlin L, Tabouret M, Bentsen C, Walsh TJ. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. J Infect Dis 2004; 190(3): 641-9.

Maertens J, Theunissen K, Verhoef G, VerschakelenJ, Lagrou K, Verbeken E, et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 2005; 41(9): 1242-50.

Adler-Moore JP, Olson JA, Proffitt RT. Alternative dosing regimens of liposomal amphotericin B (AmBisome) effective in treating murine systemic candidiasis. J Antimicrob Chemother 2004; 54(6): 1096-102.

Jack DL, Klein NJ, Turner MW. Mannose-binding lectin:targeting the microbial world for complement attack and opsonophagocytosis. Immunol Rev 2001; 180: 86-99.

Neth O, Hann I, Turner MW, Klein NJ. Deficiency of mannose-binding lectin and burden of infection in children with malignancy: a prospective study. Lancet 2001; 358(9282): 598-9.

Mantovani A, Garlanda C, Bottazzi B. Pentraxin 3, a nonredundant soluble pattern recognition receptor involved in innate immunity. Vaccine 2003; 21 Suppl 2: S43-7.

al-Ramadi BK, Ellis M, Pasqualini F, Mantovani A.Selective induction of pentraxin 3, a soluble innate immune pattern recognition receptor, in infectious episodes in patients with haematological malignancy.Clin Immunol 2004; 112(3): 221-4.

Garlanda C, Hirsch E, Bozza S, Salustri A, De Acetis M,Nota R, et al. Non-redundant role of the long pentraxin PTX3 in anti-fungal innate immune response. Nature 2002; 420(6912): 182-6.

Bajetto A, Bonavia R, Barbero S, Schettini G.Characterization of chemokines and their receptors in the central nervous system: physiopathological implications.J Neurochem 2002; 82(6): 1311-29.

Cavaillon JM, Adib-Conquy M, Fitting C, Adrie C, Payen D. Cytokine cascade in sepsis. Scand J Infect Dis 2003;35(9): 535-44.

Ellis M, al-Ramadi B, Hedström U, Alizadeh H, Shammas V, Kristensen J. Invasive fungal infections are associated with severe depletion of circulating RANTES. J Med Microbiol 2005; 54(Pt 11):1017-22.

McDermott MF, Aksentijevich I, Galon J, McDermott EM,Ogunkolade BW, Centola M, et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 1999; 97(1): 133-44.

Fisher CJ Jr, Agosti JM, Opal SM, Lowry SF, Balk RA,Sadoff JC, et al. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med 1996;334(26): 1697-702.

Annane D, Sébille V, Charpentier C, Bollaert PE, François B, Korach JM, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002; 288(7): 862-71.

Nguyen HB, Rivers EP, Abrahamian FM, Moran GJ,Abraham E, Trzeciak S, et al. Severe sepsis and septic shock: review of the literature and emergency department management guidelines. Ann Emerg Med 2006; 48(1):28-54.

Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344(10): 699-709.

Ellis M, Hedstrom U, Frampton C, Alizadeh H,Kristensen J, Shammas FV, et al. Modulation of the systemic inflammatory response by recombinant human interleukin-11: a prospective randomized placebo controlled clinical study in patients with hematological malignancy. Clin Immunol 2006; 20(2): 129-37.

Clark OA, Lyman GH, Castro AA, Clark LG, Djulbegovic B. Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol 2005; 23(18): 4198-214.

Ozer H, Armitage JO, Bennett CL, Crawford J, Demetri GD, Pizzo PA, et al. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors:evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol 2000; 18(20): 3558-85.

National Comprehensive Guidelines Network. Myeloid Growth Factors. Available from:http://www.nccn.org/Accessed 7 September 2005.

Aapro MS, Cameron DA, Pettengell R, Bohlius J,Crawford J, Ellis M, et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. EurJ Cancer 2006; 42(15): 2433-53.

Add comment 

Home  Editorial Board  Search  Current Issue  Archive Issues  Announcements  Aims & Scope  About the Journal  How to Submit  Contact Us
Find out how to become a part of the HMJ  |   CLICK HERE >>
© Copyright 2012 - 2013 HMJ - HAMDAN Medical Journal. All Rights Reserved         Website Developed By Cedar Solutions INDIA